On 26 November 2010, orphan designation (EU/3/10/803) was granted by the European Commission to Ganymed Pharmaceuticals AG, Germany, for chimeric monoclonal antibody against claudin-18 splice variant 2 for the treatment of gastric cancer.
In May 2017 sponsor, Ganymed Pharmaceuticals AG changed name to Ganymed Pharmaceuticals AG GmbH.
The sponsorship was transferred to Astellas Pharma Europe B.V., The Netherlands, in March 2018.
Chimeric monoclonal antibody against claudin-18 splice variant 2
|Disease / condition||
treatment of gastric cancer
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.